Si gle-dose IBIO-610 achieved up to 98% i hibitio of active Activi E th ough eight weeks, suppo ti g a diffe e tiated, lo g-acti g a tibody app oach
Whe combi ed with semaglutide, IBIO-610 d ove g eate visce al a d total fat loss while educi g lea mass loss by 73% ve sus semaglutide alo e
Full dataset to be p ese ted at Eu opea Associatio fo the Study of Diabetes (EASD) A ual Meeti g
SAN DIEGO, July 01, 2026 (GLOBE NEWSWIRE) — iBio, I c. (NASDAQ: IBIO), a cli ical-stage biotech ology developi g lo g-acti g a tibody the apeutics fo obesity, ca diometabolic a d ca diopulmo a y diseases, today a ou ced ew p ecli ical data f om its obese o -huma p imate (NHP) study evaluati g IBIO-610, pote tially a fi st-i -class Activi E a tibody ca didate.
Followi g a si gle dose of IBIO-610, active Activi E levels i the blood we e educed i all t eated NHPs a d emai ed supp essed th ough eight weeks. At both weeks 4 a d 8, active Activi E levels we e educed to levels below the limits of the assay. Ove all, active Activi E was educed by 98% at week 4 a d 97% at week 8 compa ed with baseli e. These fi di gs suppo t IBIO-610’s pote tial fo best-i -class pathway i hibitio a d fu the suppo t the pote tial fo a i f eque tly dosed, lo g-acti g a tibody app oach.
The data also demo st ated IBIO-610’s pote tial to p omote fat-selective weight loss while p ese vi g lea mass. I obese NHPs, whe combi ed with semaglutide, IBIO-610 d ove g eate visce al a d total fat loss while educi g lea mass loss by 73% ve sus semaglutide alo e, fu the suppo ti g its pote tial as both a sta d-alo e the apy a d a compleme ta y app oach to GLP-1-based t eatme ts.
“These latest NHP data ep ese t a othe key poi t i the adva ceme t of IBIO-610 as a pote tially diffe e tiated a tibody app oach,” said Ma ti B e e , DVM, Ph.D., Chief Executive Office a d Chief Scie tific Office of iBio. “We a e pa ticula ly e cou aged to see what we believe is the highest deg ee of Activi E i hibitio epo ted to date fo a molecule i this class a d achieved followi g a si gle dose. This level of i hibitio suppo ts the pote tial fo low-f eque cy dosi g to imp ove the patie t expe ie ce. We believe Activi E blockade ep ese ts a impo ta t oppo tu ity fo iBio as the obesity ma ket co ti ues to evolve towa d mo e du able a d body-compositio -focused the apies.”
The full data will be highlighted i a p ese tatio at the 2026 EASD A ual Meeti g, taki g place Septembe 28 – Octobe 2 i Mila . Details of the p ese tatio a e listed below:
Fo mo e i fo matio , visit www.ibioi c.com o follow us o Li kedI .
Ce tai stateme ts i this p ess elease co stitute “fo wa d-looki g stateme ts” withi the mea i g of the fede al secu ities laws. Wo ds such as “may,” “might,” “will,” “should,” “believe,” “expect,” “a ticipate,” “estimate,” “co ti ue,” “p edict,” “fo ecast,” “p oject,” “pla ,” “i te d” o simila exp essio s, o stateme ts ega di g i te t, belief, o cu e t expectatio s, a e fo wa d-looki g stateme ts. These fo wa d-looki g stateme ts a e based upo cu e t estimates a d assumptio s a d i clude stateme ts ega di g IBIO-610’s pote tial fo best-i -class pathway i hibitio a d the pote tial fo a i f eque tly dosed, lo g-acti g a tibody app oach; IBIO-610’s pote tial to p omote fat-selective weight loss while p ese vi g lea mass; IBIO-610’s pote tial as both a sta d-alo e the apy a d a compleme ta y app oach to GLP-1-based t eatme ts; IBIO-610 pote tial diffe e tiated a tibody app oach; the data bei g the highest deg ee of Activi E i hibitio epo ted to date fo a molecule i this class a d achieved followi g a si gle dose; the data suppo ti g the pote tial fo low-f eque cy dosi g to imp ove the patie t expe ie ce a d the Activi E blockade ep ese ti g a impo ta t oppo tu ity fo iBio as the obesity ma ket co ti ues to evolve towa d mo e du able a d body-compositio -focused the apies While iBio believes these fo wa d-looki g stateme ts a e easo able, u due elia ce should ot be placed o a y such fo wa d-looki g stateme ts, which a e based o i fo matio available to us o the date of this elease. These fo wa d-looki g stateme ts a e subject to va ious isks a d u ce tai ties, ma y of which a e difficult to p edict that could cause actual esults to diffe mate ially f om cu e t expectatio s a d assumptio s f om those set fo th o implied by a y fo wa d-looki g stateme ts. Impo ta t facto s that could cause actual esults to diffe mate ially f om cu e t expectatio s i clude, amo g othe s, the ability of Activi E to be a successful ta get fo ca diometabolic diso de s a d obesity a d iBio’s a tibody to i duce fat-selective weight loss a d offe p otectio agai st obesity a d ca diometabolic disease; the ability to p oduce simila data i huma cli ical t ials; iBio’s ability to obtai egulato y app ovals fo comme cializatio of its p oduct ca didates, o to comply with o goi g egulato y equi eme ts; egulato y limitatio s elati g to iBio’s ability to p omote o comme cialize its p oduct ca didates fo specific i dicatio s; accepta ce of iBio’s p oduct ca didates i the ma ketplace a d the successful developme t, ma keti g o sale of p oducts; a d whethe iBio will i cu u fo esee expe ses o liabilities o othe ma ket facto s; a d the othe facto s discussed i iBio’s fili gs with the SEC i cludi g its A ual Repo t o Fo m 10-K fo the yea e ded Ju e 30, 2025 a d its subseque t fili gs with the SEC o Fo ms 10-Q a d 8-K. The i fo matio i this elease is p ovided o ly as of the date of this elease, a d iBio u de takes o obligatio to update a y fo wa d-looki g stateme ts co tai ed i this elease o accou t of ew i fo matio , futu e eve ts, o othe wise, except as equi ed by law.
